Related Experiment Video
Updated: Jul 5, 2026
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Modeling single nucleus microglia across species identifies immune pathways and therapeutic candidates in Alzheimer's
Alexander Bergendorf1,2, Jee Hyun Park1, Brendan K Ball1,3
1Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA.
Abstract:
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by memory loss and behavioral changes. A pivotal influence on AD pathology is the dysregulation of microglia in the brain. Despite promising findings in mouse models, there are limitations to the translatable biological information across species due to differences in the physiology, timeline of disease, and human heterogeneity. To address these interspecies discrepancies, we developed a novel implementation of the Translatable Components Regression (TransComp-R) framework, which integrated microglial single-nucleus transcriptomic data to identify biological pathways in mice AD models predictive of human AD. We compared model variations with sparse and traditional principal component analysis (PCA), finding that standard PCA encoded more interpretable mouse PCs compared to sPCA despite limited differences in technical performance. Mouse PCs significantly differentiated human AD from control microglial cells in the BA41/42, BA6/8, hippocampus and entorhinal cortex brain regions. However, these PCs had limited separation of human AD from control microglia in the prefrontal cortex. Additionally, we identified gene signatures from FDA-approved drugs that correlated with significant mouse component loadings, including valproic-acid and calcifediol. This computational framework may support the discovery of cross-species disease similarities, including the identification of candidate pharmacological solutions that may translate across species.
Insights
This study introduces a new computational framework to bridge the gap between mouse models and human Alzheimer's disease (AD) research. It identifies biological pathways in mice that predict human AD, aiding drug discovery.
Area of Science:
- Neuroscience
- Computational Biology
- Genomics
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder with complex pathology involving microglial dysregulation.
- Mouse models are crucial for AD research but face limitations in translatability to human conditions due to interspecies differences.
- Bridging the gap between mouse models and human AD requires novel computational approaches to identify conserved biological mechanisms.
Purpose of the Study:
- To develop and implement a novel computational framework, Translatable Components Regression (TransComp-R), for identifying cross-species conserved biological pathways in Alzheimer's disease.
- To integrate microglial single-nucleus transcriptomic data from mouse AD models and human subjects to predict human AD pathology.
- To compare different modeling approaches, including sparse and traditional principal component analysis (PCA), for their effectiveness in identifying translatable components.
Main Methods:
- Utilized a novel implementation of the Translatable Components Regression (TransComp-R) framework.
- Integrated microglial single-nucleus transcriptomic data from mouse AD models and human brain samples.
- Employed and compared sparse principal component analysis (sPCA) and traditional PCA for dimensionality reduction and component extraction.
- Analyzed gene signatures of FDA-approved drugs for correlation with identified mouse principal components.
Main Results:
- Standard PCA provided more interpretable mouse principal components (PCs) compared to sPCA, with comparable technical performance.
- Mouse PCs significantly differentiated Alzheimer's disease (AD) from control microglial cells in specific human brain regions (BA41/42, BA6/8, hippocampus, entorhinal cortex).
- Limited separation was observed in the prefrontal cortex, highlighting region-specific differences.
- Identified correlations between mouse component loadings and gene signatures of FDA-approved drugs, including valproic acid and calcifediol.
Conclusions:
- The developed TransComp-R framework effectively identifies cross-species conserved biological pathways relevant to Alzheimer's disease.
- Mouse AD models, analyzed through this framework, can provide insights predictive of human AD pathology in specific brain regions.
- This computational approach holds promise for discovering candidate pharmacological solutions that may translate from mouse models to human therapeutics for Alzheimer's disease.
